Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 356

1.

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis.

Strand V, Michalska M, Birchwood C, Pei J, Tuckwell K, Finch R, Kivitz AJ, Smolen JS, Burmester GR.

RMD Open. 2018 Jun 17;4(1):e000602. doi: 10.1136/rmdopen-2017-000602. eCollection 2018.

2.

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD.

Rheumatology (Oxford). 2018 Jun 25. doi: 10.1093/rheumatology/key161. [Epub ahead of print]

PMID:
29945203
3.

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.

Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR.

Arthritis Res Ther. 2018 Jun 19;20(1):129. doi: 10.1186/s13075-018-1614-z.

4.

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.

McInnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, Pricop L, Jugl SM, Gandhi KK; FUTURE 2 Study Group.

Arthritis Res Ther. 2018 Jun 7;20(1):113. doi: 10.1186/s13075-018-1610-3.

5.

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

Holland R, Tillett W, Ogdie A, Leung YY, Gladman DD, Callis Duffin K, Coates LC, Mease PJ, Eder L, Strand V, Elmamoun M, Højgaard P, Chau J, de Wit M, Goel N, Lindsay CA, FitzGerald O, Shea B, Beaton D, Orbai AM.

J Rheumatol Suppl. 2018 Jun;94:17-25. doi: 10.3899/jrheum.180142.

PMID:
29858348
6.

A Pooled Analysis of Two Multicenter, Randomized Controlled Trials of a Single Intra-articular Injection of Gel-200 for Treatment of Osteoarthritis of the Knee.

Takamura J, Seo T, Strand V.

Clin Med Insights Arthritis Musculoskelet Disord. 2018 May 9;11:1179544118773068. doi: 10.1177/1179544118773068. eCollection 2018.

7.

Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses.

Strand V, Kavanaugh A, Kivitz AJ, van der Heijde D, Kwok K, Akylbekova E, Soonasra A, Snyder M, Connell C, Bananis E, Smolen JS.

Rheumatol Ther. 2018 May 14. doi: 10.1007/s40744-018-0113-7. [Epub ahead of print]

8.

Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.

Strand V, Lee EB, Yazici Y, Dikranian A, Wilkinson B, Takiya L, Zang C, Bananis E, Bergman MJ.

Clin Rheumatol. 2018 Aug;37(8):2043-2053. doi: 10.1007/s10067-018-4077-3. Epub 2018 Apr 14.

PMID:
29656373
9.

Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.

Abrahamowicz M, Esdaile JM, Ramsey-Goldman R, Simon LS, Strand V, Lipsky PE.

Arthritis Rheumatol. 2018 Apr 12. doi: 10.1002/art.40522. [Epub ahead of print]

PMID:
29648686
11.

Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.

Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M.

J Manag Care Spec Pharm. 2018 Apr;24(4):344-352. doi: 10.18553/jmcp.2018.24.4.344.

12.

Rheumatoid arthritis.

Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K.

Nat Rev Dis Primers. 2018 Feb 8;4:18001. doi: 10.1038/nrdp.2018.1. Review.

PMID:
29417936
13.

Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.

van Vollenhoven RF, Keystone EC, Strand V, Pacheco-Tena C, Vencovský J, Behrens F, Racewicz A, Zipp D, Rharbaoui F, Wolter R, Knierim L, Schmeidl R, Zhou X, Aigner S, Dälken B, Wartenberg-Demand A; TREAT2b study team.

Ann Rheum Dis. 2018 Apr;77(4):495-499. doi: 10.1136/annrheumdis-2017-212478. Epub 2018 Jan 17.

PMID:
29343509
14.

Adiposity in Juvenile Psoriatic Arthritis.

Samad A, Stoll ML, Lavi I, Hsu JJ, Strand V, Robinson TN, Mellins ED, Zisman D; CARRA Legacy Registry Investigators.

J Rheumatol. 2018 Mar;45(3):411-418. doi: 10.3899/jrheum.170598. Epub 2017 Dec 15.

PMID:
29247150
15.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS.

Arthritis Rheumatol. 2018 Mar;70(3):345-355. doi: 10.1002/art.40391. Epub 2018 Feb 6.

PMID:
29193765
16.

Discordant patient-physician assessments of disease activity and its persistence adversely impact quality of life and work productivity in US Hispanics with rheumatoid arthritis.

Karpouzas GA, Ramadan SN, Cost CE, Draper TL, Hernandez E, Strand V, Ormseth SR.

RMD Open. 2017 Oct 25;3(2):e000551. doi: 10.1136/rmdopen-2017-000551. eCollection 2017.

17.

Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study.

Ballegaard C, Jørgensen TS, Skougaard M, Strand V, Mease PJ, Kristensen LE, Dreyer L, Gottlieb A, de Wit M, Christensen R, Tarp S.

Arthritis Care Res (Hoboken). 2017 Oct 26. doi: 10.1002/acr.23455. [Epub ahead of print]

PMID:
29073353
18.

Evidence of fatigue, disordered sleep and peripheral inflammation, but not increased brain TSPO expression, in seasonal allergy: A [11C]PBR28 PET study.

Tamm S, Cervenka S, Forsberg A, Estelius J, Grunewald J, Gyllfors P, Karshikoff B, Kosek E, Lampa J, Lensmar C, Strand V, Åkerstedt T, Halldin C, Ingvar M, Olgart Höglund C, Lekander M.

Brain Behav Immun. 2018 Feb;68:146-157. doi: 10.1016/j.bbi.2017.10.013. Epub 2017 Oct 18.

19.

A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative.

Højgaard P, Klokker L, Orbai AM, Holmsted K, Bartels EM, Leung YY, Goel N, de Wit M, Gladman DD, Mease P, Dreyer L, Kristensen LE, FitzGerald O, Tillett W, Gossec L, Helliwell P, Strand V, Ogdie A, Terwee CB, Christensen R.

Semin Arthritis Rheum. 2018 Apr;47(5):654-665. doi: 10.1016/j.semarthrit.2017.09.002. Epub 2017 Sep 9. Review.

PMID:
29037523
20.

Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials.

Strand V, Michalska M, Birchwood C, Pei J, Tuckwell K, Finch R, Gabay C, Kavanaugh A, Jones G.

RMD Open. 2017 Sep 14;3(2):e000496. doi: 10.1136/rmdopen-2017-000496. eCollection 2017.

21.

Patient Burden of Axial Spondyloarthritis.

Strand V, Singh JA.

J Clin Rheumatol. 2017 Oct;23(7):383-391. doi: 10.1097/RHU.0000000000000589. Review.

22.

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry.

Strand V, Miller P, Williams SA, Saunders K, Grant S, Kremer J.

Rheumatol Ther. 2017 Dec;4(2):489-502. doi: 10.1007/s40744-017-0078-y. Epub 2017 Aug 22.

23.

Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016.

Morgan EM, Riebschleger MP, Horonjeff J, Consolaro A, Munro JE, Thornhill S, Beukelman T, Brunner HI, Creek EL, Harris JG, Horton DB, Lovell DJ, Mannion ML, Olson JC, Rahimi H, Gallo MC, Calandra S, Ravelli A, Ringold S, Shenoi S, Stinson J, Toupin-April K, Strand V, Bingham CO 3rd.

J Rheumatol. 2017 Dec;44(12):1884-1888. doi: 10.3899/jrheum.161389. Epub 2017 Aug 15.

PMID:
28811355
24.

The unmet need in rheumatology: Reports from the targeted therapies meeting 2017.

Winthrop KL, Strand V, van der Heijde D, Mease P, Crow M, Weinblatt M, Bathon J, Burmester GR, Dougados M, Kay J, Mariette X, Van Vollenhoven R, Sieper J, Melchers F, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Clin Immunol. 2018 Jan;186:87-93. doi: 10.1016/j.clim.2017.08.009. Epub 2017 Aug 12.

PMID:
28811201
25.

Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets.

Tunis SR, Maxwell LJ, Graham ID, Shea BJ, Beaton DE, Bingham CO 3rd, Brooks P, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March LM, Simon LS, Singh JA, Strand V, Wells GA, Tugwell P.

J Rheumatol. 2017 Oct;44(10):1551-1559. doi: 10.3899/jrheum.161273. Epub 2017 Aug 1.

PMID:
28765256
26.

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison.

Strand V, Betts KA, Mittal M, Song J, Skup M, Joshi A.

Rheumatol Ther. 2017 Dec;4(2):349-362. doi: 10.1007/s40744-017-0070-6. Epub 2017 Jul 31.

27.

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies.

Tillett W, Orbai AM, Ogdie A, Leung YY, Strand V, Gladman DD, Mease PJ, Coates LC; GRAPPA OMERACT Psoriatic Arthritis working group.

Ann Rheum Dis. 2018 May;77(5):e23. doi: 10.1136/annrheumdis-2017-212004. Epub 2017 Jul 26. No abstract available.

PMID:
28747326
28.

Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report.

Zamora NV, Christensen R, Goel N, Klokker L, Lopez-Olivo MA, Kristensen LE, Carmona L, Strand V, Curtis JR, Suarez-Almazor ME.

J Rheumatol. 2017 Dec;44(12):1894-1898. doi: 10.3899/jrheum.161108. Epub 2017 Jun 15.

PMID:
28620065
29.

Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.

BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8. Review.

30.

Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group.

Ogdie A, de Wit M, Callis Duffin K, Campbell W, Chau J, Coates LC, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, James J, Kalyoncu U, Latella J, Lindsay C, Mease PJ, O'Sullivan D, Steinkoenig I, Strand V, Tillett W, Orbai AM.

J Rheumatol. 2017 May;44(5):697-700. doi: 10.3899/jrheum.170150.

31.

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.

Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y, Pacheco-Tena C, Fleischmann R.

RMD Open. 2017 Mar 7;3(1):e000416. doi: 10.1136/rmdopen-2016-000416. eCollection 2017.

33.

Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.

Jansen JP, Incerti D, Mutebi A, Peneva D, MacEwan JP, Stolshek B, Kaur P, Gharaibeh M, Strand V.

J Med Econ. 2017 Jul;20(7):703-714. doi: 10.1080/13696998.2017.1307205. Epub 2017 Apr 5.

PMID:
28294642
34.
35.

Evaluation and Management of the Patient With Suspected Inflammatory Spine Disease.

Strand V, Singh JA.

Mayo Clin Proc. 2017 Apr;92(4):555-564. doi: 10.1016/j.mayocp.2016.12.008. Epub 2017 Feb 21. Review.

36.

Low-dose SoluMatrix diclofenac in patients with osteoarthritis pain: impact on quality of life in a controlled trial.

Strand V, Bergman M, Singh JA, Gibofsky A, Kivitz A, Young C.

Clin Rheumatol. 2017 Jun;36(6):1357-1367. doi: 10.1007/s10067-017-3569-x. Epub 2017 Feb 13.

PMID:
28194525
37.

The Juvenile Psoriatic Arthritis Cohort in the CARRA Registry: Clinical Characteristics, Classification, and Outcomes.

Zisman D, Gladman DD, Stoll ML, Strand V, Lavi I, Hsu JJ, Mellins ED; CARRA Legacy Registry Investigators.

J Rheumatol. 2017 Mar;44(3):342-351. doi: 10.3899/jrheum.160717. Epub 2017 Feb 1.

PMID:
28148698
38.

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016.

Orbai AM, de Wit M, Mease PJ, Callis Duffin K, Elmamoun M, Tillett W, Campbell W, FitzGerald O, Gladman DD, Goel N, Gossec L, Hoejgaard P, Leung YY, Lindsay C, Strand V, van der Heijde DM, Shea B, Christensen R, Coates L, Eder L, McHugh N, Kalyoncu U, Steinkoenig I, Ogdie A.

J Rheumatol. 2017 Oct;44(10):1522-1528. doi: 10.3899/jrheum.160904. Epub 2017 Feb 1. Erratum in: J Rheumatol. 2017 Apr;44(4):543.

39.

Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study.

Kristensen LE, Jørgensen TS, Christensen R, Gudbergsen H, Dreyer L, Ballegaard C, Jacobsson LTH, Strand V, Mease PJ, Kjellberg J.

Ann Rheum Dis. 2017 Sep;76(9):1495-1501. doi: 10.1136/annrheumdis-2016-210579. Epub 2017 Jan 30.

PMID:
28137915
40.

The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar.

Strand V, Girolomoni G, Schiestl M, Ernst Mayer R, Friccius-Quecke H, McCamish M.

Curr Med Res Opin. 2017 Jun;33(6):993-1003. doi: 10.1080/03007995.2017.1288612. Epub 2017 Feb 7. Review.

PMID:
28133979
41.

From mechanism to therapies in systemic lupus erythematosus.

Paley MA, Strand V, Kim AH.

Curr Opin Rheumatol. 2017 Mar;29(2):178-186. doi: 10.1097/BOR.0000000000000369. Review.

PMID:
28118202
42.

Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies.

Schulze-Koops H, Strand V, Nduaka C, DeMasi R, Wallenstein G, Kwok K, Wang L.

Rheumatology (Oxford). 2017 Jan;56(1):46-57. doi: 10.1093/rheumatology/kew329. Epub 2016 Oct 22.

PMID:
28028154
43.

Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trials.

Peterfy C, Strand V, Tian L, Østergaard M, Lu Y, DiCarlo J, Countryman P, Deodhar A, Landewé R, Ranganath VK, Troum O, Conaghan PG.

Ann Rheum Dis. 2017 Jun;76(6):992-997. doi: 10.1136/annrheumdis-2016-210311. Epub 2016 Dec 14.

PMID:
27974302
44.
45.

Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial.

Strand V, Lee EB, Fleischmann R, Alten RE, Koncz T, Zwillich SH, Gruben D, Wilkinson B, Krishnaswami S, Wallenstein G.

RMD Open. 2016 Sep 28;2(2):e000308. eCollection 2016.

46.

Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.

Strand V, Husni E, Griffith J, Zhou ZY, Signorovitch J, Ganguli A.

Rheumatol Ther. 2016 Dec;3(2):305-322. Epub 2016 Sep 15.

47.

Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group.

Klokker L, Tugwell P, Furst DE, Devoe D, Williamson P, Terwee CB, Suarez-Almazor ME, Strand V, Woodworth T, Leong AL, Goel N, Boers M, Brooks PM, Simon LS, Christensen R.

J Rheumatol. 2017 Dec;44(12):1916-1919. doi: 10.3899/jrheum.161105. Epub 2016 Oct 15.

PMID:
27744393
48.

Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT).

de Wit M, Kirwan JR, Tugwell P, Beaton D, Boers M, Brooks P, Collins S, Conaghan PG, D'Agostino MA, Hofstetter C, Hughes R, Leong A, Lyddiatt A, March L, May J, Montie P, Richards P, Simon LS, Singh JA, Strand V, Voshaar M, Bingham CO 3rd, Gossec L.

Patient. 2017 Apr;10(2):141-152. doi: 10.1007/s40271-016-0198-4.

49.

Importance of 'meeting of the minds': patient-reported outcomes and MRI.

Ranganath VK, Strand V.

Ann Rheum Dis. 2017 Mar;76(3):473-475. doi: 10.1136/annrheumdis-2016-210058. Epub 2016 Sep 29. No abstract available.

PMID:
27689734
50.

Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.

Wallace DJ, Strand V, Merrill JT, Popa S, Spindler AJ, Eimon A, Petri M, Smolen JS, Wajdula J, Christensen J, Li C, Diehl A, Vincent MS, Beebe J, Healey P, Sridharan S.

Ann Rheum Dis. 2017 Mar;76(3):534-542. doi: 10.1136/annrheumdis-2016-209668. Epub 2016 Sep 26.

Supplemental Content

Loading ...
Support Center